mitoxantrone has been researched along with Heart Diseases in 50 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
Heart Diseases: Pathological conditions involving the HEART including its structural and functional abnormalities.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In a Phase II study, flavopiridol 50 mg/m(2) was given by 1-h infusion daily x 3 beginning day 1 followed by 2 g/m(2)/72 h ara-C beginning day 6 and 40 mg/m(2) mitoxantrone on day 9 (FLAM) to 45 adults with newly diagnosed acute myelogenous leukemia (AML) with multiple poor-risk features." | 9.14 | Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. ( Alino, K; Blackford, A; Bolaños-Meade, J; Carraway, HE; Doyle, LA; Gore, SD; Greer, JM; Jones, RJ; Karp, JE; Levis, MJ; McDevitt, MA; Seung, AH; Smith, BD; Wright, JJ, 2010) |
| "Previous studies showed that mitoxantrone can reduce disability progression in patients with multiple sclerosis (MS)." | 9.11 | Assessment of potential cardiotoxic side effects of mitoxantrone in patients with multiple sclerosis. ( Brandt, T; Gross, A; Hohlfeld, R; Jahn, K; Nabauer, M; Strupp, M; Zingler, VC, 2005) |
| "The purpose of this study was to determine the maximum-tolerated dose of gemcitabine plus mitoxantrone in women with metastatic breast cancer (MBC) and to evaluate activity and toxicity of this combination in a phase II trial." | 9.10 | Phase I/II study of gemcitabine plus mitoxantrone as salvage chemotherapy in metastatic breast cancer. ( Calabrese, P; Caporusso, L; Catino, A; Crucitta, E; D'Amico, C; De Lena, M; Guida, M; Latorre, A; Lorusso, V; Mazzei, A; Sambiasi, D; Schittulli, F; Silvestris, N, 2003) |
| "Forty chemotherapy naive patients with metastatic or locally advanced breast cancer were treated in a randomized trial comparing mitozantrone 14 mg/m2 with epirubicin 75 mg/m2 given intravenously at 3-weekly intervals." | 9.08 | Comparison of mitozantrone and epirubicin in advanced breast cancer. ( Chambers, EJ; Cook, AM; Rees, GJ, 1996) |
| "To compare myocyte cell damage induced by doxorubicin or mitoxantrone, we performed left ventricular ejection fraction (LVEF) measurements and indium 111 antimyosin antibody studies in a group of patients with advanced breast cancer who had been treated with these anthracycline derivatives." | 9.07 | Myocyte cell damage after administration of doxorubicin or mitoxantrone in breast cancer patients assessed by indium 111 antimyosin monoclonal antibody studies. ( Alonso, C; Berná, L; Carrió, I; Estorch, M; Martínez-Duncker, D; Ojeda, B; Torres, G, 1993) |
| "Three hundred twenty-five women with metastatic adenocarcinoma of the breast who had failed one prior chemotherapeutic regimen for advanced disease were randomized to receive 14 mg/m2 of mitoxantrone or 75 mg/m2 of doxorubicin intravenously (IV) every 3 weeks." | 9.06 | Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. ( Allegra, JC; Bryan, S; Cartwright, K; Dukart, G; Henderson, IC; Henry, D; Wolff, S; Woodcock, T, 1989) |
| "To exploit possible different non-cross-resistant mechanisms of cytotoxicity, 25 patients with advanced breast cancer were given combination chemotherapy consisting of iv mitoxantrone (7 mg/m2) and doxorubicin (30 mg/m2) every 3-4 weeks." | 9.06 | Phase II trial of a combination of doxorubicin and mitoxantrone in metastatic breast cancer. ( Ford, JM; Leclerc, Y; Margolese, R; Panasci, L, 1987) |
| "Mitoxantrone, an immunosuppressant agent with potent anti-inflammatory activity, has been used to treat patients with multiple sclerosis (MS) who have worsening relapsing-remitting (RRMS) or secondary progressive multiple sclerosis (SPMS) despite prior therapy with interferons or glatiramer acetate." | 8.83 | The cardiac effects of mitoxantrone: do the benefits in multiple sclerosis outweigh the risks? ( Murray, TJ, 2006) |
| "Age is a known susceptibility factor for the cardiotoxicity of several anticancer drugs, including mitoxantrone (MTX)." | 7.81 | The age factor for mitoxantrone's cardiotoxicity: multiple doses render the adult mouse heart more susceptible to injury. ( Bastos, Mde L; Carvalho, F; Costa, VM; Dores-Sousa, JL; Duarte, JA; Seabra, V, 2015) |
| "Mitoxantrone (MTX) has been shown to reduce progression of disability and number of clinical exacerbations in patients with progressive multiple sclerosis (MS)." | 7.80 | The N-terminal pro-brain natriuretic peptide as a marker of mitoxantrone-induced cardiotoxicity in multiple sclerosis patients. ( Kamińska, AM; Kochanowski, J; Kwieciński, H; Opolski, G; Podlecka-Piętowska, A; Zakrzewska-Pniewska, B, 2014) |
| "A total of 56 heavily pretreated patients with advanced breast cancer were treated with the combination mitomycin and mitoxantrone." | 7.67 | Mitomycin and mitoxantrone in previously treated patients with advanced breast cancer. ( Bishop, JF; Burns, I; Coates, A; Hillcoat, BL; Jeal, PN; Raghavan, D; Tattersall, MN; Woods, R, 1987) |
| "Eighteen women with metastatic breast cancer entered a phase I-II study of high-dose mitoxantrone (MXT)." | 7.67 | High-dose mitoxantrone in metastatic breast cancer: a phase I-II trial. ( Leiby, JM; Neidhart, JA; Unverfurth, DV, 1986) |
| "Mitoxantrone is an anthracenedione, showing structural similarities to doxorubicin." | 5.27 | An EORTC phase II study of mitoxantrone in solid tumors and lymphomas. ( Armand, JP; Bastit, P; Cappelaere, P; De Jager, R; Earl, H; Fargeot, P; Keiling, R; Renard, J; Rubens, R; van Glabbeke, M, 1984) |
| "Mitoxantrone is an active well-tolerated agent in the treatment of advanced breast carcinoma, but the risk of neutropenia requires careful supervision." | 5.27 | Mitoxantrone: an active new agent in the treatment of advanced breast cancer. ( Bozek, T; Pavlidis, NA; Smith, IE; Stuart-Harris, RC, 1984) |
| " In a Phase II study, flavopiridol 50 mg/m(2) was given by 1-h infusion daily x 3 beginning day 1 followed by 2 g/m(2)/72 h ara-C beginning day 6 and 40 mg/m(2) mitoxantrone on day 9 (FLAM) to 45 adults with newly diagnosed acute myelogenous leukemia (AML) with multiple poor-risk features." | 5.14 | Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. ( Alino, K; Blackford, A; Bolaños-Meade, J; Carraway, HE; Doyle, LA; Gore, SD; Greer, JM; Jones, RJ; Karp, JE; Levis, MJ; McDevitt, MA; Seung, AH; Smith, BD; Wright, JJ, 2010) |
| "Previous studies showed that mitoxantrone can reduce disability progression in patients with multiple sclerosis (MS)." | 5.11 | Assessment of potential cardiotoxic side effects of mitoxantrone in patients with multiple sclerosis. ( Brandt, T; Gross, A; Hohlfeld, R; Jahn, K; Nabauer, M; Strupp, M; Zingler, VC, 2005) |
| "The purpose of this study was to determine the maximum-tolerated dose of gemcitabine plus mitoxantrone in women with metastatic breast cancer (MBC) and to evaluate activity and toxicity of this combination in a phase II trial." | 5.10 | Phase I/II study of gemcitabine plus mitoxantrone as salvage chemotherapy in metastatic breast cancer. ( Calabrese, P; Caporusso, L; Catino, A; Crucitta, E; D'Amico, C; De Lena, M; Guida, M; Latorre, A; Lorusso, V; Mazzei, A; Sambiasi, D; Schittulli, F; Silvestris, N, 2003) |
| "Forty chemotherapy naive patients with metastatic or locally advanced breast cancer were treated in a randomized trial comparing mitozantrone 14 mg/m2 with epirubicin 75 mg/m2 given intravenously at 3-weekly intervals." | 5.08 | Comparison of mitozantrone and epirubicin in advanced breast cancer. ( Chambers, EJ; Cook, AM; Rees, GJ, 1996) |
| "To compare myocyte cell damage induced by doxorubicin or mitoxantrone, we performed left ventricular ejection fraction (LVEF) measurements and indium 111 antimyosin antibody studies in a group of patients with advanced breast cancer who had been treated with these anthracycline derivatives." | 5.07 | Myocyte cell damage after administration of doxorubicin or mitoxantrone in breast cancer patients assessed by indium 111 antimyosin monoclonal antibody studies. ( Alonso, C; Berná, L; Carrió, I; Estorch, M; Martínez-Duncker, D; Ojeda, B; Torres, G, 1993) |
| "To exploit possible different non-cross-resistant mechanisms of cytotoxicity, 25 patients with advanced breast cancer were given combination chemotherapy consisting of iv mitoxantrone (7 mg/m2) and doxorubicin (30 mg/m2) every 3-4 weeks." | 5.06 | Phase II trial of a combination of doxorubicin and mitoxantrone in metastatic breast cancer. ( Ford, JM; Leclerc, Y; Margolese, R; Panasci, L, 1987) |
| "Three hundred twenty-five women with metastatic adenocarcinoma of the breast who had failed one prior chemotherapeutic regimen for advanced disease were randomized to receive 14 mg/m2 of mitoxantrone or 75 mg/m2 of doxorubicin intravenously (IV) every 3 weeks." | 5.06 | Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. ( Allegra, JC; Bryan, S; Cartwright, K; Dukart, G; Henderson, IC; Henry, D; Wolff, S; Woodcock, T, 1989) |
| "Mitoxantrone, an immunosuppressant agent with potent anti-inflammatory activity, has been used to treat patients with multiple sclerosis (MS) who have worsening relapsing-remitting (RRMS) or secondary progressive multiple sclerosis (SPMS) despite prior therapy with interferons or glatiramer acetate." | 4.83 | The cardiac effects of mitoxantrone: do the benefits in multiple sclerosis outweigh the risks? ( Murray, TJ, 2006) |
| "Age is a known susceptibility factor for the cardiotoxicity of several anticancer drugs, including mitoxantrone (MTX)." | 3.81 | The age factor for mitoxantrone's cardiotoxicity: multiple doses render the adult mouse heart more susceptible to injury. ( Bastos, Mde L; Carvalho, F; Costa, VM; Dores-Sousa, JL; Duarte, JA; Seabra, V, 2015) |
| "Mitoxantrone (MTX) has been shown to reduce progression of disability and number of clinical exacerbations in patients with progressive multiple sclerosis (MS)." | 3.80 | The N-terminal pro-brain natriuretic peptide as a marker of mitoxantrone-induced cardiotoxicity in multiple sclerosis patients. ( Kamińska, AM; Kochanowski, J; Kwieciński, H; Opolski, G; Podlecka-Piętowska, A; Zakrzewska-Pniewska, B, 2014) |
| "A total of 56 heavily pretreated patients with advanced breast cancer were treated with the combination mitomycin and mitoxantrone." | 3.67 | Mitomycin and mitoxantrone in previously treated patients with advanced breast cancer. ( Bishop, JF; Burns, I; Coates, A; Hillcoat, BL; Jeal, PN; Raghavan, D; Tattersall, MN; Woods, R, 1987) |
| "Mitoxantrone, an anthracenedione derivative structurally similar to anthracycline, was tested in 25 Phase II patients with advanced breast cancer, previously treated with different cycles of 5-fluorouracil." | 3.67 | Evaluation of ventricular function by echocardiography and radionuclide angiography in patients treated with mitoxantrone. ( Crippa, F; Galimberti, M; Villani, F, 1989) |
| "Fourteen patients with advanced breast cancer were treated with a combination of vincristine, mitozantrone and prednisolone." | 3.67 | Cardiotoxicity of mitozantrone assessed by stress and resting nuclear ventriculography. ( Cassidy, J; Leonard, RC; Merrick, MV; Smyth, JF, 1988) |
| "Eighteen women with metastatic breast cancer entered a phase I-II study of high-dose mitoxantrone (MXT)." | 3.67 | High-dose mitoxantrone in metastatic breast cancer: a phase I-II trial. ( Leiby, JM; Neidhart, JA; Unverfurth, DV, 1986) |
| "Mitoxantrone was administered as a single iv injection once every 3 weeks to 84 children with advanced acute leukemia and solid tumors in a phase I trial." | 3.67 | Phase I trial of mitoxantrone in children. ( Cohen, LF; Glaubiger, DL; Holcenberg, JS; Kamen, BA; Pratt, CB; Ungerleider, RS; Vietti, TJ, 1985) |
| "Unfortunately, cardiotoxicity is a severe and common adverse effect in MTX-treated patients." | 1.56 | Mitoxantrone impairs proteasome activity and prompts early energetic and proteomic changes in HL-1 cardiomyocytes at clinically relevant concentrations. ( Almeida, MG; Capela, JP; Carvalho, F; Carvalho, RA; Costa, VM; Dores-Sousa, JL; Duarte, JA; Eleutério, RP; Lourdes Bastos, M; Remião, F; Rodrigues, PRS; Sousa, JR; Varner, KJ, 2020) |
| "Chrysin (CHR) is a natural flavonoid and is present in high concentration in honey, propolis and many plant extracts." | 1.42 | Chrysin attenuates cardiomyocyte apoptosis and loss of intermediate filaments in a mouse model of mitoxantrone cardiotoxicity. ( Anghel, N; Ardelean, A; Balta, C; Cotoraci, C; Galajda, Z; Herman, H; Hermenean, A; Ivan, A; Nicolescu, L; Olariu, T; Suciu, M, 2015) |
| "Mitoxantrone (MTX) is a chemotherapeutic agent, which presents late irreversible cardiotoxicity." | 1.40 | Mitochondrial cumulative damage induced by mitoxantrone: late onset cardiac energetic impairment. ( Amado, F; Arbo, M; Costa, VM; Dallegrave, E; de Lourdes Bastos, M; Dinis-Oliveira, RJ; Duarte, JA; Ferreira, R; Palmeira, C; Remião, F; Rossato, LG; Silva, R, 2014) |
| "Mitoxantrone (MTX) is an antitumor agent that causes cardiotoxicity in 18 % patients." | 1.39 | The metabolic profile of mitoxantrone and its relation with mitoxantrone-induced cardiotoxicity. ( Arbo, MD; Costa, VM; de Freitas, V; de Lourdes Bastos, M; de Pinho, PG; Palmeira, C; Remião, F; Rossato, LG; Vilain, L, 2013) |
| " In addition, ICRF-187 allowed for 50% greater cumulative dosing in normal mice that, nonetheless, showed extensive histological heart damage 7 wk after dosing." | 1.29 | Characterization of experimental mitoxantrone cardiotoxicity and its partial inhibition by ICRF-187 in cultured neonatal rat heart cells. ( Alberts, DS; Dawson, BV; Dorr, RT; Hendrix, M; Shipp, NG, 1993) |
| "Cardiotoxicity is a well recognized side effect of anthracyclines (doxorubicin and epirubicin) or antracenadiones (mitoxantrone) at cumulative or high doses." | 1.29 | Late cardiac toxicity of doxorubicin, epirubicin, and mitoxantrone therapy for Hodgkin's disease in adults. ( Arévila, N; Avilés, A; Díaz Maqueo, JC; García, R; Gómez, T; Nambo, MJ, 1993) |
| "Responses of the Hodgkin's disease to this therapy were favourable but short-lived." | 1.28 | High-dose mitoxantrone and etoposide conditioning in autologous bone marrow transplantation for relapsed Hodgkin's disease. ( Baglin, TP; Flavell, DJ; Flavell, SU; Lim, SH; Marcus, RE; Wimperis, JZ, 1992) |
| "Mitoxantrone is an active well-tolerated agent in the treatment of advanced breast carcinoma, but the risk of neutropenia requires careful supervision." | 1.27 | Mitoxantrone: an active new agent in the treatment of advanced breast cancer. ( Bozek, T; Pavlidis, NA; Smith, IE; Stuart-Harris, RC, 1984) |
| "Mitoxantrone is an anthracenedione, showing structural similarities to doxorubicin." | 1.27 | An EORTC phase II study of mitoxantrone in solid tumors and lymphomas. ( Armand, JP; Bastit, P; Cappelaere, P; De Jager, R; Earl, H; Fargeot, P; Keiling, R; Renard, J; Rubens, R; van Glabbeke, M, 1984) |
| "Thirty-five patients with hepatocellular carcinoma (HCC) have been treated with the Anthracenedione derivative, Mitozantrone." | 1.27 | Mitozantrone as single agent therapy in hepatocellular carcinoma. A phase II study. ( Dunk, AA; Johnson, PJ; Lok, AS; Melia, W; Murray-Lyon, I; Scott, SC; Thomas, HC; Williams, R, 1985) |
| "To determine optimal dosage, Dihydroxyanthracenedione (DHAD) was given once daily for 3 days at dosage levels of 6, 7, 8, and 10 mg/m2 in combination with a 7-day continuous infusion of cytosine arabinoside (Ara-C)." | 1.27 | Toxicity evaluation of dihydroxyanthracenedione (DHAD) in combination with cytosine arabinoside (Ara-C). ( Civin, CI; Krischer, J; Land, VJ; Ragab, AH; Steuber, CP; Vietti, TJ, 1987) |
| "Two percent had congestive heart failure associated with doxorubicin." | 1.27 | Early and delayed clinical cardiotoxicity of doxorubicin. ( Blumenschein, GR; Buzdar, AU; Marcus, C; Smith, TL, 1985) |
| " 10-fold less toxic than doxorubicin and caused only minor electrocardiogram (ECG) changes." | 1.26 | Comparison of cardiotoxicity of two anthracenediones and doxorubicin in rats. ( Beilstein, AK; Zbinden, G, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 22 (44.00) | 18.7374 |
| 1990's | 12 (24.00) | 18.2507 |
| 2000's | 8 (16.00) | 29.6817 |
| 2010's | 7 (14.00) | 24.3611 |
| 2020's | 1 (2.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sami, SM | 1 |
| Dorr, RT | 2 |
| Sólyom, AM | 1 |
| Alberts, DS | 3 |
| Remers, WA | 1 |
| Costa, VM | 4 |
| Capela, JP | 1 |
| Sousa, JR | 1 |
| Eleutério, RP | 1 |
| Rodrigues, PRS | 1 |
| Dores-Sousa, JL | 2 |
| Carvalho, RA | 1 |
| Lourdes Bastos, M | 1 |
| Duarte, JA | 3 |
| Remião, F | 3 |
| Almeida, MG | 1 |
| Varner, KJ | 1 |
| Carvalho, F | 2 |
| Rossato, LG | 2 |
| de Pinho, PG | 1 |
| Arbo, MD | 1 |
| de Freitas, V | 1 |
| Vilain, L | 1 |
| de Lourdes Bastos, M | 2 |
| Palmeira, C | 2 |
| Dallegrave, E | 1 |
| Arbo, M | 1 |
| Silva, R | 1 |
| Ferreira, R | 1 |
| Amado, F | 1 |
| Dinis-Oliveira, RJ | 1 |
| Podlecka-Piętowska, A | 1 |
| Kochanowski, J | 1 |
| Zakrzewska-Pniewska, B | 1 |
| Opolski, G | 1 |
| Kwieciński, H | 1 |
| Kamińska, AM | 1 |
| Seabra, V | 1 |
| Bastos, Mde L | 1 |
| Anghel, N | 1 |
| Cotoraci, C | 1 |
| Ivan, A | 1 |
| Suciu, M | 1 |
| Herman, H | 1 |
| Balta, C | 1 |
| Nicolescu, L | 1 |
| Olariu, T | 1 |
| Galajda, Z | 1 |
| Ardelean, A | 1 |
| Hermenean, A | 1 |
| Damiani, RM | 1 |
| Moura, DJ | 1 |
| Viau, CM | 1 |
| Caceres, RA | 1 |
| Henriques, JAP | 1 |
| Saffi, J | 1 |
| Jakl, M | 1 |
| Horacek, JM | 1 |
| Jebavy, L | 1 |
| Pudil, R | 1 |
| Karp, JE | 1 |
| Blackford, A | 1 |
| Smith, BD | 1 |
| Alino, K | 1 |
| Seung, AH | 1 |
| Bolaños-Meade, J | 1 |
| Greer, JM | 1 |
| Carraway, HE | 1 |
| Gore, SD | 1 |
| Jones, RJ | 1 |
| Levis, MJ | 1 |
| McDevitt, MA | 1 |
| Doyle, LA | 1 |
| Wright, JJ | 1 |
| Lorusso, V | 1 |
| Crucitta, E | 1 |
| Silvestris, N | 1 |
| Catino, A | 1 |
| Caporusso, L | 1 |
| Mazzei, A | 1 |
| Guida, M | 1 |
| Latorre, A | 1 |
| Sambiasi, D | 1 |
| D'Amico, C | 1 |
| Schittulli, F | 1 |
| Calabrese, P | 1 |
| De Lena, M | 1 |
| van Dalen, EC | 1 |
| van der Pal, HJ | 1 |
| Bakker, PJ | 1 |
| Caron, HN | 1 |
| Kremer, LC | 1 |
| Avilés, A | 2 |
| Neri, N | 1 |
| Nambo, JM | 1 |
| Huerta-Guzman, J | 1 |
| Talavera, A | 1 |
| Cleto, S | 1 |
| Zingler, VC | 1 |
| Nabauer, M | 1 |
| Jahn, K | 1 |
| Gross, A | 1 |
| Hohlfeld, R | 1 |
| Brandt, T | 1 |
| Strupp, M | 1 |
| Murray, TJ | 1 |
| Tan, RM | 1 |
| Quah, TC | 1 |
| Aung, L | 1 |
| Liang, S | 1 |
| Kirk, RC | 1 |
| Yeoh, AE | 1 |
| Kimler, BF | 1 |
| Mansfield, CM | 1 |
| Svoboda, DJ | 1 |
| Cox, GG | 1 |
| De Jager, R | 1 |
| Cappelaere, P | 1 |
| Armand, JP | 2 |
| Keiling, R | 1 |
| Fargeot, P | 1 |
| Bastit, P | 1 |
| van Glabbeke, M | 1 |
| Renard, J | 1 |
| Earl, H | 1 |
| Rubens, R | 1 |
| Aapro, MS | 1 |
| Woolfenden, JM | 1 |
| Mackel, C | 1 |
| Stuart-Harris, RC | 1 |
| Bozek, T | 1 |
| Pavlidis, NA | 1 |
| Smith, IE | 1 |
| Zbinden, G | 1 |
| Beilstein, AK | 1 |
| Bezwoda, WR | 1 |
| Seymour, L | 1 |
| Dansey, RD | 1 |
| de Forni, M | 1 |
| Sonneveld, P | 1 |
| Hop, W | 1 |
| Mulder, AH | 1 |
| Michiels, JJ | 1 |
| Blijham, G | 1 |
| van de Lelie, J | 1 |
| Raemakers, JW | 1 |
| Nieuwenhuis, K | 1 |
| van der Heul, C | 1 |
| Arévila, N | 1 |
| Díaz Maqueo, JC | 1 |
| Gómez, T | 1 |
| García, R | 1 |
| Nambo, MJ | 1 |
| Estorch, M | 1 |
| Carrió, I | 1 |
| Martínez-Duncker, D | 1 |
| Berná, L | 1 |
| Torres, G | 1 |
| Alonso, C | 1 |
| Ojeda, B | 1 |
| Shipp, NG | 1 |
| Dawson, BV | 1 |
| Hendrix, M | 1 |
| Cook, AM | 1 |
| Chambers, EJ | 1 |
| Rees, GJ | 1 |
| Lemez, P | 1 |
| Maresová, J | 1 |
| Gralow, JR | 1 |
| Livingston, RB | 1 |
| Lim, SH | 1 |
| Baglin, TP | 1 |
| Flavell, DJ | 1 |
| Flavell, SU | 1 |
| Wimperis, JZ | 1 |
| Marcus, RE | 1 |
| Schlumberger, M | 1 |
| Parmentier, C | 1 |
| Delisle, MJ | 1 |
| Couette, JE | 1 |
| Droz, JP | 1 |
| Sarrazin, D | 1 |
| Doria, G | 1 |
| Cangemi, F | 1 |
| Tosto, A | 1 |
| Platania, F | 1 |
| Circo, A | 1 |
| Motta, S | 1 |
| Tralongo, P | 1 |
| Aiello, RA | 1 |
| Failla, G | 1 |
| Bishop, JF | 1 |
| Raghavan, D | 1 |
| Woods, R | 1 |
| Coates, A | 1 |
| Burns, I | 1 |
| Jeal, PN | 1 |
| Hillcoat, BL | 1 |
| Tattersall, MN | 1 |
| Henderson, IC | 1 |
| Allegra, JC | 1 |
| Woodcock, T | 1 |
| Wolff, S | 1 |
| Bryan, S | 1 |
| Cartwright, K | 1 |
| Dukart, G | 2 |
| Henry, D | 1 |
| Villani, F | 1 |
| Galimberti, M | 1 |
| Crippa, F | 1 |
| Dunk, AA | 1 |
| Scott, SC | 1 |
| Johnson, PJ | 1 |
| Melia, W | 1 |
| Lok, AS | 1 |
| Murray-Lyon, I | 1 |
| Williams, R | 1 |
| Thomas, HC | 1 |
| Cassidy, J | 1 |
| Merrick, MV | 1 |
| Smyth, JF | 1 |
| Leonard, RC | 1 |
| Ford, JM | 1 |
| Panasci, L | 1 |
| Leclerc, Y | 1 |
| Margolese, R | 1 |
| Saletan, S | 1 |
| Elisson, O | 1 |
| Hiddemann, W | 1 |
| Kreutzmann, H | 1 |
| Straif, K | 1 |
| Ludwig, WD | 1 |
| Mertelsmann, R | 1 |
| Donhuijsen-Ant, R | 1 |
| Lengfelder, E | 1 |
| Arlin, Z | 1 |
| Büchner, T | 1 |
| Steuber, CP | 1 |
| Land, VJ | 1 |
| Civin, CI | 1 |
| Ragab, AH | 1 |
| Krischer, J | 1 |
| Vietti, TJ | 2 |
| Shenkenberg, TD | 1 |
| Von Hoff, DD | 2 |
| Mather, FJ | 1 |
| Simon, RM | 1 |
| Clark, GM | 1 |
| Foss-Abrahamsen, A | 1 |
| Lenner, P | 1 |
| Hedenus, M | 1 |
| Landys, K | 1 |
| Noppa, H | 1 |
| Leiby, JM | 1 |
| Unverfurth, DV | 1 |
| Neidhart, JA | 1 |
| Ungerleider, RS | 1 |
| Pratt, CB | 1 |
| Holcenberg, JS | 1 |
| Kamen, BA | 1 |
| Glaubiger, DL | 1 |
| Cohen, LF | 1 |
| Buzdar, AU | 1 |
| Marcus, C | 1 |
| Smith, TL | 1 |
| Blumenschein, GR | 1 |
| Iatropoulos, MJ | 1 |
| Yacobi, A | 1 |
6 reviews available for mitoxantrone and Heart Diseases
| Article | Year |
|---|---|
Pathways of cardiac toxicity: comparison between chemotherapeutic drugs doxorubicin and mitoxantrone.
Topics: Animals; Antibiotics, Antineoplastic; Antigens, Neoplasm; Cardiotoxicity; DNA Topoisomerases, Type I | 2016 |
Cumulative incidence and risk factors of mitoxantrone-induced cardiotoxicity in children: a systematic review.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Clinical Trials as Topic; Heart Diseases | 2004 |
The cardiac effects of mitoxantrone: do the benefits in multiple sclerosis outweigh the risks?
Topics: Disease Progression; Heart; Heart Diseases; Humans; Immunosuppressive Agents; Leukemia; Mitoxantrone | 2006 |
Cardiotoxicity of chemotherapy.
Topics: Alkylating Agents; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combi | 1994 |
Mitoxantrone: an active, new antitumor agent with an improved therapeutic index.
Topics: Breast Neoplasms; Clinical Trials as Topic; Doxorubicin; Female; Heart Diseases; Humans; Mitoxantron | 1987 |
Mitoxantrone: a new anticancer drug with significant clinical activity.
Topics: Adult; Animals; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Child; Clinical Trials as T | 1986 |
14 trials available for mitoxantrone and Heart Diseases
| Article | Year |
|---|---|
Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.
Topics: Adult; Aged; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantatio | 2010 |
Phase I/II study of gemcitabine plus mitoxantrone as salvage chemotherapy in metastatic breast cancer.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug | 2003 |
Late cardiac toxicity secondary to treatment in Hodgkin's disease. A study comparing doxorubicin, epirubicin and mitoxantrone in combined therapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Disease-F | 2005 |
Assessment of potential cardiotoxic side effects of mitoxantrone in patients with multiple sclerosis.
Topics: Adult; Aged; Anti-Inflammatory Agents; Drug Therapy, Combination; Echocardiography; Female; Heart; H | 2005 |
High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplant | 1995 |
Full-dose chemotherapy for non-Hodgkin's lymphoma in the elderly. Dutch Hematology-Oncology in Adults Study Group.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 1994 |
Myocyte cell damage after administration of doxorubicin or mitoxantrone in breast cancer patients assessed by indium 111 antimyosin monoclonal antibody studies.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasm | 1993 |
Comparison of mitozantrone and epirubicin in advanced breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Epirubicin; Heart Diseases; Humans; Middle Aged; Mitoxantro | 1996 |
Efficacy of dexrazoxane as a cardioprotective agent in patients receiving mitoxantrone- and daunorubicin-based chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Agents; Daunorubicin; Female; | 1998 |
Combination therapy for anaplastic giant cell thyroid carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality | 1991 |
Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer.
Topics: Adenocarcinoma; Breast Neoplasms; Clinical Trials as Topic; Doxorubicin; Drug Evaluation; Female; He | 1989 |
Phase II trial of a combination of doxorubicin and mitoxantrone in metastatic breast cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Tr | 1987 |
Mitoxantrone: an active, new antitumor agent with an improved therapeutic index.
Topics: Breast Neoplasms; Clinical Trials as Topic; Doxorubicin; Female; Heart Diseases; Humans; Mitoxantron | 1987 |
Mitoxantrone: a new anticancer drug with significant clinical activity.
Topics: Adult; Animals; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Child; Clinical Trials as T | 1986 |
32 other studies available for mitoxantrone and Heart Diseases
| Article | Year |
|---|---|
Amino-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H- dibenz[de,h]isoquinoline-1,3-diones. Synthesis, antitumor activity, and quantitative structure--activity relationship.
Topics: Adenine; Animals; Antineoplastic Agents; Cattle; Colonic Neoplasms; DNA; Doxorubicin; Heart Diseases | 1995 |
Mitoxantrone impairs proteasome activity and prompts early energetic and proteomic changes in HL-1 cardiomyocytes at clinically relevant concentrations.
Topics: Animals; Apoptosis Regulatory Proteins; Cardiotoxicity; Cell Line; Dose-Response Relationship, Drug; | 2020 |
The metabolic profile of mitoxantrone and its relation with mitoxantrone-induced cardiotoxicity.
Topics: Animals; Antineoplastic Agents; Cytochrome P-450 CYP2E1; Cytochrome P-450 Enzyme System; Dose-Respon | 2013 |
Mitochondrial cumulative damage induced by mitoxantrone: late onset cardiac energetic impairment.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Biomarkers; Electron Transport Complex IV; E | 2014 |
The N-terminal pro-brain natriuretic peptide as a marker of mitoxantrone-induced cardiotoxicity in multiple sclerosis patients.
Topics: Adult; Antineoplastic Agents; Biomarkers; Cardiomyopathies; Female; Heart Diseases; Heart Failure; H | 2014 |
The age factor for mitoxantrone's cardiotoxicity: multiple doses render the adult mouse heart more susceptible to injury.
Topics: Age Factors; Animals; Antineoplastic Agents; Aspartate Aminotransferases; Biomarkers; Body Weight; C | 2015 |
Chrysin attenuates cardiomyocyte apoptosis and loss of intermediate filaments in a mouse model of mitoxantrone cardiotoxicity.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Creatine Kinase, M | 2015 |
Continuous 24-h monitoring of electrocardiogram during anthracycline-based therapy in acute leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cardiotoxins; Cytarabine; Daunorubicin; Electr | 2009 |
Improved outcome in childhood acute myeloid leukemia in Singapore with the MRC AML 10 protocol.
Topics: Acute Disease; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chemical and | 2007 |
Ultrastructural evidence of cardiac damage resulting from thoracic irradiation and anthracyclines in the rat.
Topics: Animals; Anthraquinones; Antineoplastic Agents; Doxorubicin; Heart; Heart Diseases; Male; Microscopy | 1984 |
An EORTC phase II study of mitoxantrone in solid tumors and lymphomas.
Topics: Adolescent; Adult; Aged; Alopecia; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Carcinom | 1984 |
Prospective study of left ventricular function using radionuclide scans in patients receiving mitoxantrone.
Topics: Aged; Anthraquinones; Antineoplastic Agents; Coronary Circulation; Doxorubicin; Female; Heart; Heart | 1983 |
Mitoxantrone: an active new agent in the treatment of advanced breast cancer.
Topics: Adult; Aged; Agranulocytosis; Anthraquinones; Breast Neoplasms; Doxorubicin; Drug Evaluation; Female | 1984 |
Comparison of cardiotoxicity of two anthracenediones and doxorubicin in rats.
Topics: Animals; Anthraquinones; Antibiotics, Antineoplastic; Blood Cell Count; Doxorubicin; Electrocardiogr | 1982 |
Late cardiac toxicity of doxorubicin, epirubicin, and mitoxantrone therapy for Hodgkin's disease in adults.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Epirubicin; Female; Follow-Up St | 1993 |
Characterization of experimental mitoxantrone cardiotoxicity and its partial inhibition by ICRF-187 in cultured neonatal rat heart cells.
Topics: Adenosine Triphosphate; Animals; Cells, Cultured; Dose-Response Relationship, Drug; Heart Diseases; | 1993 |
University of Washington high-dose cyclophosphamide, mitoxantrone, and etoposide experience in metastatic breast cancer: unexpected cardiac toxicity.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II a | 2001 |
High-dose mitoxantrone and etoposide conditioning in autologous bone marrow transplantation for relapsed Hodgkin's disease.
Topics: Adult; Bone Marrow Transplantation; Etoposide; Female; Heart Diseases; Hodgkin Disease; Humans; Male | 1992 |
[Evaluation of acute cardiotoxicity from the combination cyclophosphamide-mitoxantrone-5-fluorouracil (CMF) with Holter ECG].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Electrocardiography, Ambulatory; F | 1990 |
Mitomycin and mitoxantrone in previously treated patients with advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Heart Diseases; Hematologic Diseas | 1987 |
Evaluation of ventricular function by echocardiography and radionuclide angiography in patients treated with mitoxantrone.
Topics: Adult; Breast Neoplasms; Drug Evaluation; Echocardiography; Electrocardiography; Female; Heart Disea | 1989 |
Mitozantrone as single agent therapy in hepatocellular carcinoma. A phase II study.
Topics: Adult; Aged; Anthraquinones; Carcinoma, Hepatocellular; Child; Drug Evaluation; Female; Heart Diseas | 1985 |
Cardiotoxicity of mitozantrone assessed by stress and resting nuclear ventriculography.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Heart Disease | 1988 |
Assessment of ventricular function by radionuclide angiography in patients receiving 4'-epidoxorubicin and mitoxantrone.
Topics: Anthraquinones; Doxorubicin; Epirubicin; Heart Diseases; Humans; Mitoxantrone | 1986 |
High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cytarabine; | 1987 |
Toxicity evaluation of dihydroxyanthracenedione (DHAD) in combination with cytosine arabinoside (Ara-C).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Hea | 1987 |
Cardiotoxicity in patients treated with mitoxantrone: Southwest Oncology Group phase II studies.
Topics: Dose-Response Relationship, Drug; Drug Evaluation; Heart Diseases; Humans; Mitoxantrone; Risk; Time | 1987 |
Mitoxantrone in the treatment of patients with non-Hodgkin's Lymphoma.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Female; Heart Diseases; Hematopoiesis; Humans; Lympho | 1987 |
High-dose mitoxantrone in metastatic breast cancer: a phase I-II trial.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Dose-Response Relationship, Dr | 1986 |
Phase I trial of mitoxantrone in children.
Topics: Acute Disease; Adolescent; Agranulocytosis; Anthraquinones; Child; Child, Preschool; Dose-Response R | 1985 |
Early and delayed clinical cardiotoxicity of doxorubicin.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Cardiomyopathies; Cyclo | 1985 |
Comment on mitoxantrone.
Topics: Animals; Anthraquinones; Antibiotics, Antineoplastic; Dogs; Doxorubicin; Heart Diseases; Humans; Mit | 1985 |